Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug...

Full description

Bibliographic Details
Main Authors: Francisco José Toja-Camba, Laura García-Quintanilla, Lorena Rodríguez-Martinez, Julia Tomine, Francisco Cajade-Pascual, Carolina Feitosa, Irene Zarra-Ferro, Manuel Barreiro-De-Acosta, Jaime González-López, Cristina Mondelo-García, Anxo Fernández-Ferreiro
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Pharmaceutics
Subjects:
point-of-care
infliximab
adalimumab
anti-drug antibodies
ELISA
Online Access:https://www.mdpi.com/1999-4923/15/11/2615

Internet

https://www.mdpi.com/1999-4923/15/11/2615

Similar Items